To determine the maximum tolerated dose (MTD) of the combination of gemcitabine and topotecan in women with previously treated epithelial ovarian, peritoneal, or fallopian tube cancer. Methods. Patients with recurrent...
Objectives. To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity o...
Objective. To investigate weekly topotecan in heavily pretreated patients with recurrent ovarian cancer. Methods. The records of patients with recurrent epithelial ovarian cancer who were treated with weekly topotecan...
The long- term survival of patients with epithelial ovarian cancer is limited by the emergence of tumor cells that are resistant to chemotherapy. We hypothesized that expression of Bcl- xL,a homologue of Bcl- 2 that c...
Preclinical and clinical data have d emonstrated the impor-tance of schedule in optimizing the c ytotoxic potential of topotecan,one of the most active age nts in ovarian cancer.The availability of oral topotecan p er...
Objective. Incorporating topotecan into standard platinum/taxane chem otherapy for advanced ovarian cancer has been complicated by myelosuppression. This study evaluated sequential doublets of topotecan and carboplati...